Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.69
0.021.20%
At close: May 18, 5:00 PM EST
$1.69
N/A
After Hours: 4:35 PM EST
Cardiff Oncology Inc Analyst Ratings
CRDFNASDAQ
Earnings: Q1 2026 Earnings were released on Thu May 14th, after the market close
Cardiff Oncology Analyst Ratings and Price Targets | NASDAQ:CRDF | Benzinga
Cardiff Oncology Inc has a consensus price target of $9.93 based on the ratings of 7 analysts. The high is $19 issued by Ladenburg Thalmann on July 8, 2025. The low is $3.5 issued by Jefferies on June 24, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on February 25, 2026, January 28, 2026, and August 6, 2025, respectively. With an average price target of $8.67 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 412.82% upside for Cardiff Oncology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Ladenburg Thalmann
Jefferies
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Cardiff Oncology
Loading calendar...
FAQ
What is the target price for Cardiff Oncology (CRDF) stock?
The latest price target for Cardiff Oncology (NASDAQ:CRDF) was reported by Piper Sandler on February 25, 2026. The analyst firm set a price target for $6.00 expecting CRDF to rise to within 12 months (a possible 255.03% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
The latest analyst rating for Cardiff Oncology (NASDAQ:CRDF) was provided by Piper Sandler, and Cardiff Oncology maintained their overweight rating.
When was the last upgrade for Cardiff Oncology (CRDF)?
There is no last upgrade for Cardiff Oncology
When was the last downgrade for Cardiff Oncology (CRDF)?
There is no last downgrade for Cardiff Oncology.
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on February 25, 2026 so you should expect the next rating to be made available sometime around February 25, 2027.
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $10.00 to $6.00. The current price Cardiff Oncology (CRDF) is trading at is $1.69, which is out of the analyst’s predicted range.
